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1.371 for the 6MV beams, TrueBeam and Versa HD, 
respectively. The same figure for the 10MV beams were 
1.484-1.524, and 1.501-1.543. Concerning beam penetration, 
TPR20,10 for 6 and 10 flattened and FFF TrueBeam beams 
were: 0.665, 0.629 (6MV) and 0.738, 0.703 (10MV), while for 
Versa HD beams are: 0.684, 0.678 (6MV) and 0.734, 0.721 
(10MV). 
 
Conclusion: Renormalization factor and unflatness 
parameters proved to be efficient to describe the FFF beam 
characteristics. Renormalization factors here presented could 
be used for all TrueBeam and Versa HD beams, without the 
need of recalculate them for the site specific conditions. 
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Purpose or Objective: Monte Carlo calculations are 
increasingly applied as an independent QA tool for pre-
treatment verification of patient plans for complex 
treatment delivery techniques such as VMAT. The dose 
obtained is usually imported to the treatment planning 
system for further analysis. The analysis can encompass 
visual comparison of dose distributions as well as qualitative 
and/or quantitative comparison of Dose Volume Histograms 
for specific structures. More sophisticated quantitative 
comparison in 3D includes gamma analysis combining dose 
difference and distance-to-agreement evaluation generating 
pass/fail maps. The normalized dose difference (NDD) 
method is considered to be an extension of the gamma-index 
concept including locally defined, spatially varying 
normalization factors. The NDD is reported to be insensitive 
to the dose grid size. Also, it shows which dose distribution 
has a higher value at the comparison point (has a sign).  
The objective of the work is to test the applicability of the 
NDD method in the Monte Carlo pre-treatment QA procedure, 
as well as to develop a stand-alone module which will include 
visual and quantitative analysis. 
 
Material and Methods: Monte Carlo simulations were 
performed using the EGSnrc/BEAMnrc code system with 
modifications, capable to compute dose distributions due to 
a continuously moving gantry, dynamic multileaf collimator 
and variable dose rate (I.A. Popescu and J. Lobo, Radiother. 
Onc.2007). A Monte Carlo model of a Varian Clinac iX 
accelerator was used. Patient treatment plans were 
generated by Eclipse treatment planning system (Varian 
Medical Systems, USA) and calculated by the AAA algorithm. 
NDD formalism has been applied in Matlab (Mathworks®) as 
described in (Jiang SB, et al. Phys Med Biol 2006). 
 
Results: Dose distributions for patients in different 
anatomical regions have been obtained; pelvic and head and 
neck. Example of NDD analysis for a prostate cancer is shown 
in the figure.  
 
 
 
A 3%, 3 mm tolerance criteria is used. The colour scale varies 
from ±3%, i.e. the region of acceptance. Negative values 
indicate that the Eclipse dose (AAA) is lower than the Monte 
Carlo calculated dose. The Monte Carlo simulations include 
the air surrounding the patient. Therefore the NDD values 
outside the patient are negative. All the NDD values are 
within tolerance on the left transversal slice, i.e. there is 
agreement between Monte Carlo and AAA. On the right 
transversal slice, the AAA shows higher target dose in small 
ventral regions and lower dose at some points in the risk 
organ (rectum). In general the pass-rate observed is > 95%. A 
slight dominance of the Monte Carlo dose has been observed 
in the NDD statistics expressed as a shift of the maximum in 
the NDD distribution. 
 
Conclusion: The NDD method can give important information 
for pre-treatment verification of VMAT plans, which is 
complementary to the dose analysis in the treatment 
planning system. 
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Purpose or Objective: To evaluate the usefulness and 
accuracy of a commercially available plastic scintillator 
(Exradin W1) for use in in vivo proton therapy skin dosimetry. 
 
Material and Methods: Six patients undergoing passive 
scatter proton therapy for prostate cancer were enrolled in 
an IRB approved protocol. The Exradin W1 plastic scintillator 
was used to measure in vivo skin dose by attaching the 
detector to the patient’s skin at the central axis of each 
treatment field (2 laterally opposed treatment fields). 
Measurements were acquired once per week for the entire 
treatment course resulting in a total of 93 measurements. 
The detector was first calibrated on a Cobalt-60 unit, and 
phantom measurements in the proton beam with the W1 and 
a calibrated parallel plane ion chamber were used to account 
for the under-response due to ionization quenching. The 
average dose difference between the Exradin W1 in vivo dose 
and parallel plane ion chamber in phantom dose over all 
measurement and per-patient was computed, as well as 
standard deviations. Furthermore, dose extracted from the 
treatment planning system was compare to the parallel plane 
ion chamber. Finally, baseline stability measurements in the 
cobalt unit were performed weekly for the duration of the 
study. 
 
Results: The calibrated detector exhibited a 7% under-
response for 225 MeV proton beams. The temperature under-
response was 4% when used at 37° C (relative to the response 
at the calibration temperature of 20° C). The detector 
exhibited a stable response and was within 1% for the 
duration of the study (144 days). The average dose difference 
between the Exradin W1 and parallel plane ion chamber over 
all patient measurements was 0.27 ± 0.67% after applying the 
temperature and quenching correction factors. The dose 
difference between the Exradin W1 in vivo measurements 
and parallel plane ion chamber for all six patients treatment 
fields throughout the study were all within ± 2% with a 
standard deviation of 0.67% (see figure 1). 
 
Figure 1 Dose difference between Exradin W1 in vivo dose 
and parallel plane ion chamber dose for every patient during 
the study. 
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Conclusion: The Exradin W1 exhibited a high level of 
accuracy for in vivo skin dosimetry measurements in passively 
scattered proton beams. The quenching correction and 
temperature corrections are easy parameters to extract. The 
detector will be useful as a verification tool for proton 
therapy patients because plastic scintillators are water 
equivalent, very small detectors (2mm diameter), accurate, 
and durable. 
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Purpose or Objective: To evaluate the accuracy of different 
lateral proton beam spreading models of two commercially 
available treatment planning systems (TPS) in optimizing 
proton pencil beam dose distributions for small targets 
located at increasing depths in water. 
 
Material and Methods: The TPSs analytical algorithms were 
benchmarked against experimental data and the FLUKA 
Monte Carlo (MC) code, previously validated for the selected 
beam-line. We tested the Siemens Syngo and the RaySearch 
RayStation TPS plan optimization modules for water cubes, 
by fixing the configurable parameters at clinical standards, 
with homogeneous target coverage to a 2 Gy (RBE) (Relative 
Biological Effectiveness) dose prescription as unique goal. An 
RBE of 1.1 has been used. For shallower targets requiring a 
range shifter, two different approaches were adopted with 
Syngo: A) the passive absorber was numerically accounted for 
its water equivalent thickness only and a single Gaussian 
approximation was considered for the lateral evolution of the 
beam; B) the passive absorber was contoured as a body 
included in the TPS calculation volume, where a double 
Gaussian modeling for the beam lateral spread is applied. 
Case B served to directly compare Syngo with the RayStation 
strategy of accounting the range shifter as a part of patient 
geometry during pencil beam tracing. Transversal and 
longitudinal profiles, acquired across target centers, were 
compared and a γ-analysis was performed within each 
volume between TPS and MC. Optimized plans were delivered 
and the dose at each volume center was measured in water 
with a calibrated PTW Advanced Markus chambers. An EBT3 
film was also positioned at the phantom entrance surface for 
the acquisition of 2D dose maps. 
 
Results: Discrepancies between TPS calculated and MC 
simulated values were mainly due to the different lateral 
spread modeling and resulted to be related to the field-to-
spot size ratio. Severe limitations were found for Syngo 
configuration A (clinical scenario), when planning on very 
small and shallower cubes. The high level of agreement 
shown between MC and Syngo configuration B and RayStation, 
regarding these challenging targets, supported the hypothesis 
that the use of a single Gaussian beam model is one of the 
main sources of dose deviations for superficial volumes. No 
major discrepancies were registered in all cases analyzed, 
either at the volume center or in the penumbra region. 
 
Conclusion: The accuracy of the TPSs was proved to be 
clinically acceptable in all cases but very small and shallow 
volumes, when a poor beam lateral spreading model is used 
(single Gaussian). Satisfactory dose calculation accuracy 
could be achieved by using either a double Gaussian 
parameterization or the RayStation version of this algorithm, 
separately handling the nuclear halo effect, for range shifter 
modeling in the TPS. In this contest, the use of MC to 
validate experimental results proved to be a reliable 
procedure for pre-treatment plan verifications. 
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Purpose or Objective: Pencil beam scanning (PBS) proton 
therapy requires the delivery of many thousand proton 
beams, each modulated for position, energy and dose, to 
provide a highly conformal patient treatment. The quality of 
the treatment is dependent on the delivery accuracy of each 
beam and at each fraction. In this work we describe the use 
of treatment log files, which are a record of the machine 
parameters for a given field delivery on a given fraction, to 
investigate the integrity of treatment delivery compared to 
the nominal planned dose, for all clinical patients treated at 
Paul Scherrer Institute on Gantry 2. 
 
Material and Methods: The dosimetry-relevant log file 
parameters are used to reconstruct the 3D dose distribution 
on the patient anatomy, using a TPS-independent dose 
calculation system developed at our institute and 
experimentally validated previously. The analysis was 
performed for all clinical treatments, both for individual 
fields and per series, and delivery quality was assessed by 
comparing the log file dose to the TPS dose, in particular by 
determining the percentage of voxels within +/- 1% of the 
nominal dose, as well as gamma index using 1% and 2mm 
criteria. 
 
Results: The mean +/-1% pass rate on the series-level is 
96.4%, though individual fields showed larger variations in 
pass rate. Furthermore, this work establishes a correlation 
between the delivery quality of a field and the beam position 
accuracy. This correlation is evident for all delivered fields 
regardless of individual patient or plan characteristics. We 
have also detailed further implementation of log file analysis 
within our clinical workflow, including the clinical evaluation 
of patient delivered dose from a problematic fraction 
delivery, the discovery and diagnosis of systematic issues in 
treatment planning or delivery workflow, extra TPS quality 
assurance, and the trending of machine performance 
following repairs or upgrades. 
 
Conclusion: We have demonstrated the usefulness of 
treatment log files in PBS proton therapy, particularly in 
regard to assessing the quality of daily treatment delivery by 
calculating 3D dose distributions on the patient anatomy and 
comparing it to the nominal TPS dose. We have presented the 
results of this analysis for every patient field and series 
delivered thus far on Gantry 2. Additionally, we have shown 
that the integrity of treatment delivery is highly correlated 
with the accuracy of spot position and believe this will be 
useful for driving machine performance improvements in the 
PBS field. 
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Purpose or Objective: Hybrid MR-Radiotherapy devices 
combine radiation treatment and excellent soft tissue 
contrast imaging, which does not deliver any additional 
radiation dose to the patient. The permanent magnetic field 
of the MRI is known to deflect the electrons during 
irradiation, influencing the dose response of ionization 
chambers [Meijsing 2009]. This work investigates the effect 
of the magnetic field on the beam quality and the 
perturbation factors for six customized Farmer chambers 
with different sensitive volumes. 
 
